



Integra LifeSciences Schedules Conference Call for Wednesday, February 27 to Discuss Fourth Quarter and Full Year 2001 Financial Results and Update Forward-Looking Financial Guidance

PLAINSBORO, N.J. Feb. 20, 2002 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART) announced that it has scheduled a conference call for 9:00 a.m. EST on Wednesday, February 27 to discuss financial results for the fourth quarter and year ended December 31, 2001 and to update forward-looking financial guidance. Financial results for the fourth quarter and full year 2001 will be announced via a news release issued before the market opens on February 27.

The upcoming conference call, which will be hosted by Stuart Essig, President and Chief Executive Officer of Integra, is open to all listeners and will be followed by a question and answer session. Additional forward-looking information may be discussed in the question and answer session following the call.

Access to the live call is available by dialing (706) 679-0769 or through a listen-only webcast via a link provided on the home page of Integra's website at <http://www.Integra-LS.com>. A replay of the conference call will be accessible starting one hour following the live event. Access to the replay is available through March 12, 2002 by dialing (706) 645-9291 (access code 3162354) or through the webcast accessible on our home page.

Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. The Company has approximately 600 permanent employees.

Statements made in the upcoming conference call may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted results. Forward-looking factors that may be discussed include, but are not limited to, expected future financial results, new product development, governmental approvals, market potential, expected sales and potential therapeutic applications of new products, and additional business acquisitions. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K/A for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

Contact:
Integra LifeSciences Holdings Corporation, Plainsboro
John Bostjancic, Senior Director of Finance
(609) 936-2239
jbostjancic@integra-ls.com